Work

FDA Approval of the JAK Inhibitor Ruxolitinib and the Management of Patients with Myelofibrosis

Year: 2012

Type: article

Source: The Hematologist

DOI: 10.1182/hem.v9.2.1182

Author: Jason Gotlib

Institutions: Stanford Medicine, Stanford University

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3083035973

FWCI:

Cites: 9

Cited by:

Related to: 10